Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10594-10602

  Agoulnik, Irina U ^a   Vaid, Ajula ^a,b   Nakka, Manjula ^a   Alvarado, Misty ^a   Bingman III, William E ^a   Erdem, Halime ^a,b   Frolov, Anna ^a   Smith, Carolyn L ^a   Ayala, Gustavo E ^a   Ittmann, Michael M ^a,b   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; NUCLEAR RECEPTOR COACTIVATOR 2;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EXON; GENE INDUCTION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRON; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRONS; MALE; METRIBOLONE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR RECEPTOR COACTIVATOR 2; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; THYMIDINE;

EID: 33751304953     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1023     Document Type: Article

References (29)

1. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
2. Agoulnik IU, Vaid A, Bingman WE III, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959-67.
3. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
4. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
5. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
6. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
7. Ma H, Hong H, Huang SM, et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 1999;19:6164-73.
8. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
9. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
10. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
11. Dutertre M, Smith CL. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-α: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 2003;17:1296-314.
12. Agoulnik IU, Krause WC, Bingman WE III, et al. Repressors of androgen and progesterone receptor action. J Biol Chem 2003;278:31136-48.
13. Nazareth LV, Stenoien DL, Bingman WE III, et al. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol 1999;13:2065-75.
14. Polnaszek N, Kwabi-Addo B, Peterson L, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003;63:5724-60.
15. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003;63:6244-51.
16. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30:419-24.
17. Monia BP. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. Ciba Found Symp 1997;209:107-23.
18. Cavarretta IT, Mukopadhyay R, Lonard DM, et al. Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERα transcriptional activity and MCF-7 proliferation. Mol Endocrinol 2002;16:253-70.
19. Narayanan R, Adigun AA, Edwards DP, Weigel NL. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 2005;25:264-77.
20. Averboukh L, Liang P, Kantoff PW, Pardee AB. Regulation of S100P expression by androgen. Prostate 1996;29:350-5.
21. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
22. Xu LL, Shanmugam N, Segawa T, et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000;66:257-63.
23. Anazawa Y, Arakawa H, Nakagawa H, Nakamura Y. Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway. Oncogene 2004l;23:7621-7.
24. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 1989;49:3474-81.
25. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928-34.
26. Zhou HJ, Yan J, Luo W, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976-83.
27. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005;19:631-42.
28. Narayanan R, Edwards DP, Weigel NL. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol 2005;25:2885-98.
29. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279:7119-30.